title: How should viability of Borrelia burgdorferi be demonstrated?
authors.forename: R B
authors.initials: RB
authors.lastname: Nadelman
authors.forename: J
authors.initials: J
authors.lastname: Nowakowski
authors.forename: G P
authors.initials: GP
authors.lastname: Wormser
authors.forename: I
authors.initials: I
authors.lastname: Schwartz
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015748:Borrelia burgdorferi Group / Q000235:genetics / Q000302:isolation & purification*; D004269:DNA, Bacterial / Q000302:isolation & purification; D005356:Fibromyalgia / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D008193:Lyme Disease / Q000150:complications* / Q000188:drug therapy; D018482:Muscle, Skeletal / Q000382:microbiology*; D016133:Polymerase Chain Reaction
chemical_list: D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial